Physiologic, hemodynamic and morphologic changes of tumor vasculature are complex and heterogenous among various region of a tumor and among various tumor types. This due to the heterogeneity of the morphology of the tumor vessels, changes in rheologic property of the blood components, and changes in the interstitial pressure of the surrounding stroma. The widely accepted standard for quantification of angiogenesis is intratumoral vessel count. However, vessel count is limited by: 1) random sampling of biopsy specimen; and 2) tissue biopsy requirement, which is invasive and not practical for monitoring the changes after treatment. Non-invasive quantification of these changes in the tumor vasculature, in addition to vessel count would provide novel and essential methods to monitor the effects of the treatment, and particularly, anti-angiogenic therapy.
Specific aims are as follows: 1. To quantify tumor blood flow, tumor blood volume, mean transit time, and capillary permeability using high-resolution, multislice CT following rapid bolus of IV contrast enhancement in tumor models in mice. We will use the mathematical model developed by T-Y Lee (collaborator) to quantify the above parameters and compare them with vessel count. 2. To quantify the effects of anti-angiogenic therapy on tumor blood flow, tumor blood volume, mean transit time, and capillary permeability fraction by using CT tumor perfusion in mice. CT scan will be used to examine the anti-angiogenic effect of SU-6668. The changes in the above parameters will be compared with vessel counts and tumor cell apoptosis as determined by immunohistochemistry. If we are successful in correlating the parameters of tumor perfusion with vessel counts, this developmental project can be expanded to a full project to quantify the effects of various anti-angiogenic agents and correlate the changes with the biologic effects of those agents. The technique has the potential for use during in situ monitoring of anti- angiogenic therapy in clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA090810-01
Application #
6481695
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-07-16
Project End
2005-12-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Wang, Ruoning; Jung, Sung Yun; Wu, Chuan Fen et al. (2010) Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation. Proc Natl Acad Sci U S A 107:19885-90
Kopetz, Scott; Hoff, Paulo M; Morris, Jeffrey S et al. (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453-9
Connelly, Sarah F; Isley, Beth A; Baker, Cheryl H et al. (2010) Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells. Mol Carcinog 49:1007-21
Trepel, Martin; Stoneham, Charlotte A; Eleftherohorinou, Hariklia et al. (2009) A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer. Mol Cancer Ther 8:2383-91
Ng, Chaan S; Kodama, Yoshihisa; Mullani, Nizar A et al. (2009) Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. J Comput Assist Tomogr 33:460-5
Wang, Wei; Shao, Ruping; Wu, Qingping et al. (2009) Targeting gelatinases with a near-infrared fluorescent cyclic His-Try-Gly-Phe peptide. Mol Imaging Biol 11:424-33
Kim, M P; Park, S I; Kopetz, S et al. (2009) Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 335:249-59
Kopetz, Scott; Lesslie, Donald P; Dallas, Nikolas A et al. (2009) Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69:3842-9
Nie, Jing; Chang, Benny; Traktuev, Dmitry O et al. (2008) IFATS collection: Combinatorial peptides identify alpha5beta1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells. Stem Cells 26:2735-45
Urbanczyk-Pearson, Lauren M; Femia, Frank J; Smith, Jeffrey et al. (2008) Mechanistic investigation of beta-galactosidase-activated MR contrast agents. Inorg Chem 47:56-68

Showing the most recent 10 out of 84 publications